Login to Your Account

Pharma: Other News To Note

Thursday, September 20, 2012

• Janssen Biotech Inc., of Horsham, Pa., a unit of Johnson & Johnson, said it submitted a biologics license application requesting approval of an intravenous formulation of anti-tumor necrosis factor-alpha drug Simponi (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription